Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models

Copanlisib is a pan–class I phosphoinositide 3-kinase (PI3K) inhibitor with preferred activity toward PI3Kα and PI3Kδ. Despite the clear overall clinical benefit, the number of patients achieving complete remissions with the single agent is relatively low, a problem shared by the vast majority of ta...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Tarantelli, Chiara, Lange, Martin, Gaudio, Eugenio, Cascione, Luciano, Spriano, Filippo, Kwee, Ivo, Arribas, Alberto J., Rinaldi, Andrea, Jourdan, Thibaud, Berthold, Melanie, Sturz, Andrea, Sperl, Carolyn, Margheriti, Francesco, Scalise, Lorenzo, Gritti, Giuseppe, Rossi, Davide, Stathis, Anastasios, Liu, Ningshu, Zucca, Emanuele, Politz, Oliver, Bertoni, Francesco
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2020
Konular:
Lymphoid Neoplasia
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065481/
https://ncbi.nlm.nih.gov/pubmed/32126142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000844
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller